Trevi Therapeutics, Inc.

NASDAQ:TRVI

Biotechnology

Healthcare
$13.51 +2.63%

+$0.43 today

Market cap
$1.93B
Beta
1.05
P/E (TTM)
-53.6
EPS (TTM)
-$0.31
52W Low $5.41High $17.10

Volume 2.02M

Average 1.44M

TRVI Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Trevi Therapeutics, Inc.NASDAQ: TRVI

Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q3 FY2026 weighted avg shares (diluted) of 159.73M shares rose 10.1% year over year, behind the +21.7% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 2.0% from the prior quarter. Over 3 fiscal years it compounded at +31.0% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +10.1% toward the trailing-twelve-month pace of +21.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
159.73M+2.0% QoQ
Last fiscal yearDec 2025
145.1M+43.6% YoY
LTMSep 2026
151.86M+21.7% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.1%——
1 year+43.6%——
3-year CAGR+31.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
145.1M USD
Year-over-year change
+43.6%
4-year CAGR
+58.8%

Weighted Avg Shares (Diluted) vs competitors

How TRVI compares with its peers on the latest reported figures

  • TRVI's LTM Sep 2026 weighted avg shares (diluted) of 151.86M shares is the 3rd highest of the 9 companies compared; the peer median is 75.65M shares.
  • Its year-over-year change of +21.7% is the 4th highest of 9, against a peer median of +11.7%.
  • Over three fiscal years its annual growth of +31.0% compares with a peer median of +22.0%.
TRVI Competitors Peer median
Weighted Avg Shares (Diluted) for TRVI and competitors
Company Period LTM YoY 3-year CAGR
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026372.66M +6.8%+29.9%
ACADACADIA Pharmaceuticals Inc.LTM Sep 2026173.1M +2.8%+2.0%
TRVITrevi Therapeutics, Inc.LTM Sep 2026151.86M +21.7%+31.0%
VCREVicore Pharma Holding ABLTM Jun 2026142.11M +51.7%+47.9%
LQDALiquidia CorporationLTM Jun 202697.22M +16.5%+12.2%
UPBUpstream Bio, Inc.LTM Mar 202654.07M +4.2%+14.0%
TBPHTheravance Biopharma, Inc.LTM Mar 202651.74M +5.2%-11.2%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 202641.9M +115.2%+32.7%
TENXTenax Therapeutics, Inc.LTM Mar 202640.94M +118.4%+1187.1%
Peer median (excluding TRVI) 75.65M+11.7%+22.0%

Competitors are the stored peer set for TRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development22.98M19.83M23.68M39.38M33.48M
Selling, General & Admin9.49M10.07M10.24M12.15M15.85M
Operating Expenses32.48M29.91M33.92M51.52M49.33M
Depreciation & Amortization50K43K123K147K144K
EBITDA(32.71M)(27.98M)(28.58M)(47.79M)(42.68M)
EBITDA Margin—————
Operating Income(32.48M)(29.91M)(33.92M)(51.52M)(49.33M)
Operating Margin—————
Interest Income10K1.74M4.75M3.6M6.54M
Interest Expense1.2M780K391K4K0
Other Income / Expenses(1.49M)719K4.83M3.58M6.51M
Income Before Tax(33.96M)(29.19M)(29.1M)(47.94M)(42.82M)
Pre-Tax Margin—————
Income Tax Expense(21K)(36K)(32K)(30K)(64K)
Net Income(33.94M)(29.15M)(29.07M)(47.91M)(42.76M)
Net Margin—————
EPS (Basic)(1.49)(0.45)(0.29)(0.47)(0.29)
EPS (Diluted)(1.49)(0.45)(0.29)(0.47)(0.29)
Weighted Avg Shares22.84M64.54M99.03M101.04M145.1M
Weighted Avg Shares (Diluted)22.84M64.54M99.03M101.04M145.1M

Trevi Therapeutics, Inc.

NASDAQ:TRVI

Intrinsic Alpha fair value

Locked

Current Price

$13.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.